Immunobiology and treatment of cutaneous T-cell lymphoma.

CTCL Cutaneous T cell lymphoma Sezary syndrome cutaneous oncology immunotherapy mycosis fungoides

Journal

Expert review of clinical immunology
ISSN: 1744-8409
Titre abrégé: Expert Rev Clin Immunol
Pays: England
ID NLM: 101271248

Informations de publication

Date de publication:
07 Mar 2024
Historique:
medline: 7 3 2024
pubmed: 7 3 2024
entrez: 7 3 2024
Statut: aheadofprint

Résumé

Primary cutaneous T cell lymphomas (CTCL) are a heterogenous group of non-Hodgkin lymphomas derived from skin-homing T cells. These include mycosis fungoides and its leukemic variant Sezary syndrome, as well as the CD30+ lymphoproliferative disorders. In this review, we provide a summary of the current literature on CTCL, with a focus on the immunopathogenesis and treatment of mycosis fungoides and Sezary syndrome. Recent advances in immunology have provided new insights into the biology of malignant T cells. This in turn has led to the development of new therapies that modulate the immune system to facilitate tumor clearance or target specific aspects of tumor biology.

Identifiants

pubmed: 38450476
doi: 10.1080/1744666X.2024.2326035
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-12

Auteurs

Rishi R Goel (RR)

Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Institute for Immunology and Immune Health (I3H), Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

Alain H Rook (AH)

Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

Classifications MeSH